| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919214 | Radiotherapy and Oncology | 2013 | 7 Pages |
Abstract
Prophylactic or therapeutic HS-WBRT is expected to be associated with a low risk of undertreatment. For SCLC, it bears a minimally elevated risk of failure compared to standard WBRT. In NSCLC, HS-WBRT is most likely not associated with a clinically relevant increase in risk of failure.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Saskia Harth, Yasser Abo-Madyan, Lei Zheng, Kerstin Siebenlist, Carsten Herskind, Frederik Wenz, Frank A. Giordano,